Disease Landscape and Forecast Insights

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of PH, the potential commercial opportunities for drugs approved for…

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by the polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to…

China accounts for approximately half of the gastroesophageal cancer cases (including gastric, gastroesophageal junction, and esophageal cancer) in the world. Standard-of-care (SOC) treatments…

Clarivate Epidemiology’s coverage of acute coronary syndrome (ACS) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Obesity is a significant public health concern. Although inexpensive phentermine is commonly prescribed for weight management, newer therapies like glucagon-like peptide-1 (GLP-1) receptor agonists…

Clarivate Epidemiology’s coverage of postoperative pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of acute coronary syndrome (ACS) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute coronary syndrome patient populations covering 171 countries…

Clarivate Epidemiology’s coverage of ACS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence of ACS for each…

In 2022, sales of branded biologics in immunology exceeded $67 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

In 2022, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $150 billion in the major pharmaceutical markets under…